索拉菲尼 西罗莫司联合动脉化学治疗栓塞术在抑制肝癌肝移植术后肿瘤复发中的作用机制  

The mechanism of sorafenib and sirolimus combined with arterial chemoembolization in inhibiting tumor recurrence after liver transplantation

作　　者：张明[1] 崔子林[1] 刘子荣[1] Zhang Ming;Cui Zilin;Liu Zirong(Department of Organ Transplant Center,Tianjin First Central Hospital,Tianjin 300192,China)

机构地区：[1]天津市第一中心医院器官移植中心,300192

出　　处：《实用医技杂志》2021年第5期586-588,共3页Journal of Practical Medical Techniques

摘　　要：目的探讨索拉菲尼、西罗莫司联合动脉化学治疗栓塞术(TACE)在抑制肝癌肝移植术后肿瘤复发中的作用机制。方法选取2018—2019年在我院接受肝移植术的80例肝癌患者,按照随机数字表法将其分为研究组40例与对照组40例。肝移植术后给予患者索拉菲尼、西罗莫司预防治疗,研究组则在此基础上实施动脉化学治疗栓塞术治疗,治疗结束后检测患者肝功能指标、急性排斥反应发生情况等,并在随访0.5年后,检测患者接触蛋白(CNTN)-1、血管内皮生长因子(VEGE)-C阳性情况,记录其复发、远处转移及生存情况。结果治疗后,研究组丙氨酸转氨酶(ALT)、总胆红素(TBIL)水平低于对照组(P<0.05),2组患者白蛋白水平比较差异无统计学意义(P>0.05),患者急性排斥反应发生率低于对照组(P<0.05);随访0.5年,研究组CNTN-1、VEGE-C阳性率、复发率、远处转移率低于对照组,生存率高于对照组(P<0.05)。结论索拉菲尼、西罗莫司联合动脉化学治疗栓塞术可抑制肝癌肝移植术后肿瘤复发,有助于改善肝功能,可抑制肿瘤生长速度、细胞增殖及转移,延长患者生存时间,同时耐受性良好。Objective To explore the mechanism of sorafenib,sirolimus combined with arterial chemoemboliza-tion,trans arterial chemo embolization(TACE)in inhibiting tumor recurrence after liver transplantation.Method We select 80 liver cancer patients who underwent liver transplantation in our hospital from 2018 to 2019,and divided them into a study group(40 cases)and a control group(40 cases)according to the random number expression method.After liver transplantation,patients were given sorafenib and sirolimus preventive treatment,and the research group implemented arterial chemoembolization treatment on this basis.After the treatment,the patients′liver function indicators and the occurrence of acute rejection were tested,and After 0.5 years of follow-up,the patient′s exposure to protein(CNTN)-1 and vascular endothelial growth factor(VEGE)-C were detected,and the recurrence,distant meta-stasis and survival were recorded.Results After treatment,the levels of alanine aminotransferase(ALT)and total bilirubin(TBIL)in the study group were significantly lower than those in the control group(P<0.05),and there was no significant difference in albumin(ALB)levels between the two groups(P>0.05).The incidence of acute rejection was significantly lower than that in the control group(P>0.05);Half one years of follow-up,the positive rate of CNTN-1,VEGE-C,recurrence rate,and distant metastasis rate of the study group were significantly lower than those of the control group,and the survival rate was significantly higher than that of the control group(P<0.05).Conclusion Sorafenib and sirolimus combined with arterial chemoembolization can inhibit tumor recurrence after liver transplantation of liver cancer,help improve liver function,inhibit tumor growth,cell proliferation and metastasis,and prolong patient survival time.

关 键 词：西罗莫司 栓塞 治疗性 肝移植 抑制 化学性 复发 

分 类 号：R735.7[医药卫生—肿瘤]